NeuroSearch presents at the 11th Rodman & Renshaw Annual Healthcare Conference in New York

NeuroSearch presents at the 11th Rodman & Renshaw Annual Healthcare Conference in New York

Copenhagen, 31 August 2009 – NeuroSearch (NEUR)
will make a presentation at the 11th
Rodman & Renshaw Annual Healthcare Conference
to be held on 9–11 September
at the New York Palace Hotel, New York
NeuroSearch’s presentation is scheduled for: Friday, 11 September

at 11:40 am to 12:05 pm local time and will be held by CEO Flemming Pedersen.
In his presentation, Flemming Pedersen will give an update on NeuroSearch’s broad clinical pipeline with focus on HuntexilTM (pridopidine), a Phase III orphan drug for the treatment of Huntington’s disease, and tesofensine, a novel anti-obesity product ready for Phase III development as well as on the company’s new CNS focused drug discovery and development alliances with Eli Lilly and Janssen. The presentation will be webcasted and the link to access the audio webcast will be available at www.neurosearch.com

together with the powerpoint presentation just before the presentation will be held at the conference. Contact person: Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations, telephone: +45 4017 5103 About NeuroSearch

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ OMX Copenhagen. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and GlaxoSmithKline (GSK), and license collaboration with Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: Pridopidine (ACR16) for Huntington’s disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson’s disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase I) and NSD-721 for social anxiety disorder (Phase I). In addition, NeuroSearch has a broad